Clinical trials: Transitional Cell Carcinoma of Urinary Bladder
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
This study investigates the feasibility of the Labcorp Plasma Detect, which is an assay (test) that looks for circulating tumor DNA (ctDNA) in patients who have muscle-invasive (MI) urothelial carcinoma (also known as MI bladder…
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT07726602
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- OHSU Knight Cancer Institute
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SCH 66336 and gemcitabine may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00006351
- Testing
- gemcitabine hydrochloride, lonafarnib
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Urothelial Carcinoma, Urothelial Carcinoma Bladder
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced…
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT06823427
- Testing
- 9MW2821, Toripalimab (JS001 )
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Bladder Cancer, URINARY BLADDER
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Standard chemotherapy drugs generally work by killing rapidly dividing cells in your body. Cancers cells are some of the most rapidly dividing cells and that is why chemotherapy can be effective in some patients.
- Trial name
- NCT00714948
- Testing
- gemcitabine and cisplatin plus sorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC
This study assesses the effect of sequential radiation and durvalumab immunotherapy given as treatment prior to surgery with radical cystectomy for bladder cancer.
- Trial name
- RADIANT (NCT04543110)
- Testing
- Durvalumab, Immune Modulating Radiation
- Where
- 4 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014274
- Testing
- carboplatin, gemcitabine hydrochloride, methotrexate
- Where
- 29 sites in Austria, Belgium and 9 more
- Volunteers
- 238 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Muscle Invasive Bladder Cancer, Urothelial Carcinoma
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
The objective is to investigate the efficacy and safety of four cycles of ddMVAC with G-CSF support in patients with MIBC and locally advanced UC
- Conditions
- Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Neoadjuvant Chemotherapy
- Trial name
- NCT04047693
- Testing
- dose dense MVAC with pegylated GCSF
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Pusan National University Yangsan Hospital
Carcinoma of Urinary Tract, Urethral Carcinoma
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens.
- Conditions
- Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
- Trial name
- NCT01282463
- Testing
- Docetaxel, Ramucirumab DP, Icrucumab
- Where
- 32 sites in United States, Canada
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Transitional Cell Carcinoma of Urinary Bladder
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
The purpose of this study is to define the optimal management of localised transitional cell carcinoma (TCC) of the urinary bladder. The main objective is to evaluate whether chemoradiation is superior to radiotherapy alone.
- Trial name
- NCT00330499
- Testing
- Cisplatin, External beam radiation treatment
- Where
- 22 sites in Australia, New Zealand
- Volunteers
- 67 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Recurrent Bladder Cancer, Stage III Bladder Cancer
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery.
- Conditions
- Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT01382706
- Testing
- docetaxel, lapatinib ditosylate, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Bladder Cancer, Brain and Central Nervous System Tumors
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Esophageal Cancer, Intraocular Melanoma
- Trial name
- NCT00757614
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 14,000 people
- Sponsor
- Cancer Research UK
Bladder Cancer
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005047
- Testing
- cisplatin, doxorubicin hydrochloride, methotrexate
- Where
- 74 sites in United States, Canada
- Volunteers
- 521 people
- Sponsor
- SWOG Cancer Research Network
Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer.
- Conditions
- Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT01639521
- Testing
- cisplatin, gemcitabine hydrochloride, methotrexate
- Sponsor
- University of Southern California
Urothelial Carcinoma, Kidney Cancer
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
This is a phase 2 study of the drug denosumab for the management bone metastases from urothelial cancer. The purpose of this study is to find out how effective denosumab is in the management of bone metastases from urothelial…
- Conditions
- Urothelial Carcinoma, Kidney Cancer, Ureter Cancer, Bladder Cancer
- Trial name
- NCT03520231
- Testing
- Denosumab, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Urinary Bladder Neoplasms, Urologic Neoplasms
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC).
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- Trial name
- FORAY (NCT07827612)
- Testing
- Vepugratinib
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Eli Lilly and Company
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
This open-label, randomised, multicentre, phase 2 study (OHAI-NMIBC-01) compares toripalimab plus sequential intravesical gemcitabine followed by mitomycin C (GEM→MMC) with toripalimab alone in adults with BCG-unresponsive or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder, Non-Muscle-Invasive Bladder Cancer
- Trial name
- OHAI-NMIBC-01 (NCT07189793)
- Testing
- Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Carcinoma, Transitional Cell
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To…
- Trial name
- NCT00101842
- Testing
- Pemetrexed, Gemcitabine, Platinol
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Transitional Cell Carcinoma, Transurethral Resection
BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer
Instillation of Bacillus of Calmette-Guerin (BCG) into the urinary bladder (intravesical administration) improves rates of disease recurrence and progression after transurethral resection (TUR) of high risk, non-muscle-invasive…
- Trial name
- NCT06462001
- Testing
- Bacillus Calmette-Guerin Vaccine Intravesical, Mitomycin
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Urothelial Carcinoma, Bladder Cancer
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).
- Trial name
- NCT01042795
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Bladder Cancer
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
The purpose of this study is to find out the highest safe dose of the investigational drug CP-675,206 when given in combination with BCG therapy to patients who have experienced recurrent superficial bladder cancer after standard…
- Trial name
- NCT00880854
- Testing
- BCG and CP-675,206
- Sponsor
- University of Wisconsin, Madison